These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 3792452)

  • 1. Alterations in [Met5]- and [Leu5]enkephalin and neurotensin content in basal ganglia induced by the long-term administration of dopamine agonist and antagonist drugs to rats.
    De Ceballos ML; Boyce S; Jenner P; Marsden CD
    Eur J Pharmacol; 1986 Nov; 130(3):305-9. PubMed ID: 3792452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute effects of D-1 and D-2 dopamine receptor agonist and antagonist drugs on basal ganglia [Met5]- and [Leu5]-enkephalin and neurotensin content in the rat.
    Taylor MD; de Ceballos ML; Jenner P; Marsden CD
    Biochem Pharmacol; 1991 May; 41(9):1385-91. PubMed ID: 1673340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of a unilateral 6-hydroxydopamine lesion and prolonged L-3,4-dihydroxyphenylalanine treatment on peptidergic systems in rat basal ganglia.
    Taylor MD; De Ceballos ML; Rose S; Jenner P; Marsden CD
    Eur J Pharmacol; 1992 Aug; 219(2):183-92. PubMed ID: 1385171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Age-related decreases in the concentration of Met- and Leu-enkephalin and neurotensin in the basal ganglia of rats.
    De Ceballos ML; Boyce S; Taylor M; Jenner P; Marsden CD
    Neurosci Lett; 1987 Mar; 75(1):113-7. PubMed ID: 3574764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuropeptide levels in the basal ganglia of aged common marmosets following prolonged treatment with MPTP.
    Taylor MD; de Ceballos ML; Rose S; Chong PN; Jenner P; Marsden CD
    J Neural Transm Park Dis Dement Sect; 1991; 3(2):99-108. PubMed ID: 1716907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brain content of immunoreactive [Leu5]enkephalin and [Met5]enkephalin after pentylenetetrazol-induced convulsions.
    Vindrola O; Asai M; Zubieta M; Linares G
    Eur J Pharmacol; 1983 May; 90(1):85-9. PubMed ID: 6873178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic pharmacological manipulation of dopamine receptors in brain.
    Jenner P; Marsden CD
    Neuropharmacology; 1987 Jul; 26(7B):931-40. PubMed ID: 2889159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. D1 dopamine receptor-mediated substance P depletion in the striatonigral neurons of rats subjected to neonatal dopaminergic denervation: implications for self-injurious behavior.
    Sivam SP
    Brain Res; 1989 Oct; 500(1-2):119-30. PubMed ID: 2481560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alterations in peptide levels in Parkinson's disease and incidental Lewy body disease.
    Fernandez A; de Ceballos ML; Rose S; Jenner P; Marsden CD
    Brain; 1996 Jun; 119 ( Pt 3)():823-30. PubMed ID: 8673494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat.
    Henry B; Crossman AR; Brotchie JM
    Exp Neurol; 1999 Feb; 155(2):204-20. PubMed ID: 10072296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endogenous neurotensin attenuates dopamine-dependent locomotion and stereotypy.
    Chartoff EH; Szczypka MS; Palmiter RD; Dorsa DM
    Brain Res; 2004 Oct; 1022(1-2):71-80. PubMed ID: 15353215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dopaminergic modulation of striatal neuropeptides: differential effects of D1 and D2 receptor stimulation on somatostatin, neuropeptide Y, neurotensin, dynorphin and enkephalin.
    Engber TM; Boldry RC; Kuo S; Chase TN
    Brain Res; 1992 May; 581(2):261-8. PubMed ID: 1356580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brain endo-oligopeptidase A, a putative enkephalin converting enzyme.
    Camargo AC; Oliveira EB; Toffoletto O; Metters KM; Rossier J
    J Neurochem; 1987 Apr; 48(4):1258-63. PubMed ID: 2880931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Parkinson's disease affects differently Met5- and Leu5-enkephalin in the human brain.
    Taquet H; Javoy-Agid F; Hamon M; Legrand JC; Agid Y; Cesselin F
    Brain Res; 1983 Dec; 280(2):379-82. PubMed ID: 6652499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of opioid drugs on the release of dopamine and 5-hydroxytryptamine from rat striatum following activation of nicotinic-cholinergic receptors.
    Westfall TC; Grant H; Naes L; Meldrum M
    Eur J Pharmacol; 1983 Aug; 92(1-2):35-42. PubMed ID: 6628536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adenosine A2A and dopamine receptor interactions in basal ganglia of dopamine denervated rats.
    Carta AR; Pinna A; Tronci E; Morelli M
    Neurology; 2003 Dec; 61(11 Suppl 6):S39-43. PubMed ID: 14663008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic effects of dopamine agonists and centrally administered neurotensin on feeding.
    Hawkins MF; Barkemeyer CA; Tulley RT
    Pharmacol Biochem Behav; 1986 May; 24(5):1195-201. PubMed ID: 3725825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic MPTP treatment reduces substance P and met-enkephalin content in the basal ganglia of the marmoset.
    Pérez-Otaño I; Herrero MT; Luquin MR; Obeso JA; Del Río J
    Brain Res; 1992 Jul; 585(1-2):156-60. PubMed ID: 1380867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Possible interactions between dynorphin and dopaminergic systems in rat basal ganglia and substantia nigra.
    Quirion R; Gaudreau P; Martel JC; St-Pierre S; Zamir N
    Brain Res; 1985 Apr; 331(2):358-62. PubMed ID: 2859094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Met-enkephalin concentrations in striatum respond reciprocally to alterations in dopamine neurotransmission.
    George SR; Kertesz M
    Peptides; 1987; 8(3):487-92. PubMed ID: 2889200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.